Peptonic Medical's ongoing application for a vestibulitis patent has received a positive opinion from the international review
Peptonic Medical has previously announced that it has applied for a patent for the treatment of vestibulitis, which has been accompanied by a so-called PCT application (Patent Cooperation Treaty). This application has now been reviewed by the international review authority, the outcome is that they recommend that a patent be granted, as the patent application meets the requirements for novelty, inventive step and industrial applicability. Now it remains to submit the application at national level and get the application approved there.
The applied for patent protection concerns the treatment of vestibulitis with the Company's self-care product VagiVital® AktivGel. The background to this potential indication extension for VagiVital® AktivGel is the symptom relief VagiVital® AktivGel provides, which many sufferers of vestibulitis have testified to. The application was submitted in May 2020.
- "We are very happy about this news, that we have come one step closer to approval of the patent protection for this indication expansion. The PCT (Patent Cooperation Treaty) is an international patent system that enables companies to apply for patent protection internationally for their innovations in approximately 150 countries. Within the framework of the PCT, a preliminary assessment of patentability is made before the application proceeds to the national phase where national patent applications are submitted. Concretely, this means that you have a fairly good idea of the possibilities of obtaining patent protection for an innovation even before you submit the national patent applications," says Erik Sundquist, CEO, Peptonic Medical AB.
The next step for Peptonic Medical will be to decide in which countries the patent will be applied for, which will happen in the near future.
This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-09-2022 14:55 CET.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
E-post: erik.sundquist@peptonicmedical.se
ABOUT Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative medtech start up company, dedicated to researching and developing ground breaking products in the women’s health space and improving access to these products on a global scale.
Founded in 2009, the company now produces its own range of intimate health and wellness products under the Vagivital brand and is also the parent company of Lune Group Oy Ltd and Peptonic Medical Israel Ltd. The group is home to a holistic range of products that are trusted by experts and loved by customers. Peptonic Medical share has been traded on Spotlight (www.spotlightstockmarket.com) in Stockholm since 2014.